Circulating Tumor Cell Biomarker Panel As an Individual-level Surrogate for Survival in Metastatic Castration-resistant Prostate Cancer

Overview

Journal J Clin Oncol

Specialty Oncology

Date 2015 Mar 25

PMID 25800753

Citations 182

Authors

Howard I Scher

Glenn Heller

Arturo Molina

Gerhardt Attard

Daniel C Danila

Xiaoyu Jia

Weimin Peng

Shahneen K Sandhu

David Olmos

Ruth Riisnaes

Robert McCormack

Tomasz Burzykowski

Thian Kheoh

Martin Fleisher

Marc Buyse

Johann S de Bono

Affiliations

Soon will be listed here.

Abstract

Purpose: Trials in castration-resistant prostate cancer (CRPC) need new clinical end points that are valid surrogates for survival. We evaluated circulating tumor cell (CTC) enumeration as a surrogate outcome measure.

Patients And Methods: Examining CTCs alone and in combination with other biomarkers as a surrogate for overall survival was a secondary objective of COU-AA-301, a multinational, randomized, double-blind phase III trial of abiraterone acetate plus prednisone versus prednisone alone in patients with metastatic CRPC previously treated with docetaxel. The biomarkers were measured at baseline and 4, 8, and 12 weeks, with 12 weeks being the primary measure of interest. The Prentice criteria were applied to test candidate biomarkers as surrogates for overall survival at the individual-patient level.

Results: A biomarker panel using CTC count and lactate dehydrogenase (LDH) level was shown to satisfy the four Prentice criteria for individual-level surrogacy. Twelve-week surrogate biomarker data were available for 711 patients. The abiraterone acetate plus prednisone and prednisone-alone groups demonstrated a significant survival difference (P = .034); surrogate distribution at 12 weeks differed by treatment (P < .001); the discriminatory power of the surrogate to predict mortality was high (weighted c-index, 0.81); and adding the surrogate to the model eliminated the treatment effect on survival. Overall, 2-year survival of patients with CTCs < 5 (low risk) versus patients with CTCs ≥ 5 cells/7.5 mL of blood and LDH > 250 U/L (high risk) at 12 weeks was 46% and 2%, respectively.

Conclusion: A biomarker panel containing CTC number and LDH level was shown to be a surrogate for survival at the individual-patient level in this trial of abiraterone acetate plus prednisone versus prednisone alone for patients with metastatic CRPC. Additional trials are ongoing to validate the findings.

Citing Articles

Gravity-based microfiltration reveals unexpected prevalence of circulating tumor cell clusters in ovarian and colorectal cancer.

Meunier A, Hernandez-Castro J, Chahley N, Communal L, Kheireddine S, Koushki N Commun Med (Lond). 2025; 5(1):33.

PMID: 39900650 PMC: 11790846. DOI: 10.1038/s43856-024-00702-9.

Lessons (to be) learned from liquid biopsies: assessment of circulating cells and cell-free DNA in cancer and pregnancy-acquired microchimerism.

Bergmann L, Afflerbach A, Yuan T, Pantel K, Smit D Semin Immunopathol. 2025; 47(1):14.

PMID: 39893314 PMC: 11787191. DOI: 10.1007/s00281-025-01042-z.

Extracellular vesicles as a promising biomarker resource in liquid biopsy for cancer.

Tamura T, Yoshioka Y, Sakamoto S, Ichikawa T, Ochiya T Extracell Vesicles Circ Nucl Acids. 2024; 2(2):148-174.

PMID: 39703905 PMC: 11656527. DOI: 10.20517/evcna.2021.06.

Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer.

Goldkorn A, Tangen C, Plets M, Bsteh D, Xu T, Pinski J JAMA Netw Open. 2024; 7(10):e2437871.

PMID: 39374015 PMC: 11581504. DOI: 10.1001/jamanetworkopen.2024.37871.

The effect of tumor composition on the success of adaptive therapy: The case of metastatic Castrate-Resistant Prostate Cancer.

Salvioli M, Vandelaer L, Baena E, Schneider K, Cavill R, Stankova K PLoS One. 2024; 19(9):e0308173.

PMID: 39325718 PMC: 11426540. DOI: 10.1371/journal.pone.0308173.

References

Fleming M, Morris M, Heller G, Scher H . Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials. Nat Clin Pract Oncol. 2006; 3(12):658-67. DOI: 10.1038/ncponc0664. View

de Bono J, Scher H, Montgomery R, Parker C, Miller M, Tissing H . Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008; 14(19):6302-9. DOI: 10.1158/1078-0432.CCR-08-0872. View

Halabi S, Lin C, Kelly W, Fizazi K, Moul J, Kaplan E . Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2014; 32(7):671-7. PMC: 3927736. DOI: 10.1200/JCO.2013.52.3696. View

Reid A, Attard G, Danila D, Oommen N, Olmos D, Fong P . Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol. 2010; 28(9):1489-95. PMC: 2849770. DOI: 10.1200/JCO.2009.24.6819. View

Scher H, Jia X, de Bono J, Fleisher M, Pienta K, Raghavan D . Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol. 2009; 10(3):233-9. PMC: 2774131. DOI: 10.1016/S1470-2045(08)70340-1. View

Cohen S, Punt C, Iannotti N, Saidman B, Sabbath K, Gabrail N . Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26(19):3213-21. DOI: 10.1200/JCO.2007.15.8923. View

Petrella M, Montaner J, Batist G, Wainberg M . The role of surrogate markers in the clinical development of antiretroviral therapy: a model for early evaluation of targeted cancer drugs. Cancer Invest. 2004; 22(1):149-60. DOI: 10.1081/cnv-120027590. View

Scher H, Fizazi K, Saad F, Taplin M, Sternberg C, Miller K . Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012; 367(13):1187-97. DOI: 10.1056/NEJMoa1207506. View

Goodman Jr O, Symanowski J, Loudyi A, Fink L, Ward D, Vogelzang N . Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer. Clin Genitourin Cancer. 2011; 9(1):31-8. DOI: 10.1016/j.clgc.2011.04.001. View

10.

Scher H, Halabi S, Tannock I, Morris M, Sternberg C, Carducci M . Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008; 26(7):1148-59. PMC: 4010133. DOI: 10.1200/JCO.2007.12.4487. View

11.

Prentice R . Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med. 1989; 8(4):431-40. DOI: 10.1002/sim.4780080407. View

12.

Locke J, Guns E, Lubik A, Adomat H, Hendy S, Wood C . Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 2008; 68(15):6407-15. DOI: 10.1158/0008-5472.CAN-07-5997. View

13.

Goldkorn A, Ely B, Quinn D, Tangen C, Fink L, Xu T . Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol. 2014; 32(11):1136-42. PMC: 3970171. DOI: 10.1200/JCO.2013.51.7417. View

14.

de Bono J, Oudard S, Ozguroglu M, Hansen S, Machiels J, Kocak I . Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010; 376(9747):1147-54. DOI: 10.1016/S0140-6736(10)61389-X. View

15.

Halabi S, Small E, Kantoff P, Kattan M, Kaplan E, Dawson N . Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003; 21(7):1232-7. DOI: 10.1200/JCO.2003.06.100. View

16.

Halabi S, Small E, Hayes D, Vogelzang N, Kantoff P . Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583. J Clin Oncol. 2003; 21(3):490-5. DOI: 10.1200/JCO.2003.04.104. View

17.

Uno H, Cai T, Pencina M, DAgostino R, Wei L . On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. Stat Med. 2011; 30(10):1105-17. PMC: 3079915. DOI: 10.1002/sim.4154. View

18.

Sargent D, Wieand H, Haller D, Gray R, Benedetti J, Buyse M . Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2005; 23(34):8664-70. DOI: 10.1200/JCO.2005.01.6071. View

19.

Fizazi K, Scher H, Molina A, Logothetis C, Chi K, Jones R . Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012; 13(10):983-92. DOI: 10.1016/S1470-2045(12)70379-0. View

20.

Danila D, Morris M, de Bono J, Ryan C, Denmeade S, Smith M . Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol. 2010; 28(9):1496-501. PMC: 3040042. DOI: 10.1200/JCO.2009.25.9259. View